Sugi Predict

Sugi Predict / Compounds / SCHEMBL19337147

SCHEMBL19337147

SCHEMBL19337147

FC(F)(F)Cn1cc(-c2ccnc(Cl)n2)c2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 2/20 0.43
▸ MKNK2 Q9HBH9 5/20 0.41
▸ CDK2 P24941 2/20 0.41
▸ DYRK1B Q9Y463 1/20 0.41
▸ DYRK1A Q13627 3/20 0.39
▸ MKNK1 Q9BUB5 2/20 0.38
▸ CYP17A1 P05093 1/20 0.37
▸ PDE4B Q07343 1/20 0.37
▸ PDE4D Q08499 1/20 0.37
▸ CDK4 P11802 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ CTDSP1 Q9GZU7 1/20 0.36
▸ CA12 O43570 2/20 0.35
▸ CA1 P00915 2/20 0.35
▸ CA9 Q16790 2/20 0.35
▸ CA2 P00918 1/20 0.35
▸ GABRA1 P14867 1/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26440827 0.90 GSK3B (0.43) GSK3BMKNK2CDK2DYRK1BDYRK1A
SCHEMBL17542604 0.86 MKNK2 (0.53) GSK3BMKNK2CDK2DYRK1BDYRK1A
SCHEMBL30883818 0.85 GSK3B (0.49) GSK3BMKNK2CDK2DYRK1BDYRK1A
SCHEMBL17822343 0.85 GSK3B (0.49) GSK3BMKNK2CDK2DYRK1BDYRK1A
SCHEMBL19337064 0.82 GSK3B (0.43) GSK3BMKNK2CDK2DYRK1BDYRK1A
SCHEMBL19532488 0.81 MKNK2 (0.54) GSK3BMKNK2CDK2DYRK1BDYRK1A
SCHEMBL19254498 0.81 GSK3B (0.48) GSK3BMKNK2CDK2DYRK1BDYRK1A
SCHEMBL22585743 0.79 EGFR (0.49) GSK3BMKNK2MKNK1CDK4
SCHEMBL31278246 0.79 EGFR (0.49) GSK3BMKNK2MKNK1CDK4
SCHEMBL19103337 0.78 GSK3B (0.43) GSK3BMKNK2CDK2DYRK1BDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208967-A1 Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof INVENTISBIO CO LTD (CN) 2024-06-27 — — US disclosed
US-20230331703-A1 EGFR INHIBITORS InventisBio Co., Ltd. (CN) 2023-10-19 — — US disclosed
US-20230331703-A1 EGFR INHIBITORS InventisBio Co., Ltd. (CN) 2023-10-19 — — US disclosed
US-11639344-B2 EGFR inhibitors InventisBio Co., Ltd. (CN) 2023-05-02 — — US disclosed
US-11639344-B2 EGFR inhibitors InventisBio Co., Ltd. (CN) 2023-05-02 — — US disclosed
US-11203589-B2 Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof InventisBio Co., Ltd. (CN) 2021-12-21 — — US disclosed
CN-107793413-B Pyrimidine heterocyclic compound and preparation method and application thereof 上海科州药物研发有限公司 2021-09-28 — — CN disclosed
US-20210040068-A1 EGFR INHIBITORS InventisBio Co., Ltd. (CN) 2021-02-11 — — US disclosed
US-20190152969-A1 PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF INVENTISBIO SHANGHAI LTD. (CN) 2019-05-23 — — US disclosed
US-10179784-B2 Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof INVENTISBIO SHANGHAI LTD. (CN) 2019-01-15 — — US disclosed
CN-107793413-A Pyrimidine heterocyclic compound and its preparation method and application 天津滨江药物研发有限公司 2018-03-13 — — CN disclosed
US-20170355696-A1 PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF InventisBio Co., Ltd. (CN) 2017-12-14 — — US disclosed
US-20170355696-A1 PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF InventisBio Co., Ltd. (CN) 2017-12-14 — — US disclosed
EP-3216786-A1 PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF Shanghai Shaletech Technology Co., Ltd. (CN) 2017-09-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190152969-A1 PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF EGFR, WEE1, DPYD GSK3B 821/4885MKNK2 4665/4885CDK2 132/4885
US-20240208967-A1 Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof EGFR, WEE1, DPYD GSK3B 821/4885MKNK2 4665/4885CDK2 132/4885
US-20230331703-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 GSK3B 903/4885MKNK2 180/4885CDK2 45/4885
US-11203589-B2 Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof EGFR, WEE1, TP53 GSK3B 795/4885MKNK2 4779/4885CDK2 450/4885
US-20210040068-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 GSK3B 980/4885MKNK2 241/4885CDK2 39/4885
US-11639344-B2 EGFR inhibitors EGFR, ERBB2, ERBB3 GSK3B 980/4885MKNK2 241/4885CDK2 39/4885
US-20170355696-A1 PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF EGFR, WEE1, DPYD GSK3B 809/4885MKNK2 4629/4885CDK2 185/4885
US-10179784-B2 Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof EGFR, WEE1, DPYD GSK3B 821/4885MKNK2 4665/4885CDK2 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.